An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

被引：31

作者：

Pascual-Iglesias, Alejandro ^{[1
,2
]}

Canton, Javier ^{[3
]}

Ortega-Prieto, Ana Maria ^{[4
]}

Jimenez-Guardeno, Jose M. ^{[4
]}

Regla-Nava, Jose Angel ^{[5
,6
]}

机构：

[1] La Paz Univ Hosp, IdiPAZ, Innate Immune Response Grp, Madrid 28046, Spain

[2] La Paz Univ Hosp, IdiPAZ, Tumor Immunol Lab, Madrid 28046, Spain

[3] Int Inst Def & Secur CISDE, Seville 41007, Spain

[4] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London SE1 9RT, England

[5] Ctr Infect Dis & Vaccine Res, La Jolla Inst Immunol, La Jolla, CA 92037 USA

[6] Univ Guadalajara, Univ Ctr Hlth Sci CUCS, Dept Pathol & Microbiol, Guadalajara 44340, Mexico

来源：

PATHOGENS | 2021年 / 10卷 / 08期

关键词：

coronavirus; SARS-CoV-2; COVID-19; vaccine; clinical trial; pandemic; RESPIRATORY SYNCYTIAL VIRUS; ANIMAL-MODELS; CORONAVIRUS INFECTION; SARS; MERS; DISEASE; SAFETY; PATHOGENESIS; MUTATIONS; COUNTRIES;

D O I：

10.3390/pathogens10081030

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic all over the world. When the virus was first isolated and its genome was sequenced in the early months of 2020, the efforts to develop a vaccine began. Based on prior well-known knowledge about coronavirus, the SARS-CoV-2 spike (S) protein was selected as the main target. Currently, more than one hundred vaccines are being investigated and several of them are already authorized by medical agencies. This review summarizes and compares the current knowledge about main approaches for vaccine development, focusing on those authorized and specifically their immunogenicity, efficacy preventing severe disease, adverse side effects, protection, and ability to cope with emergent SARS-CoV-2 variants.

引用

页数：21

共 122 条

[41] Inactivated COVID-19 vaccines to make a global impact [J].

Iversen, Patrick L. ;

Bavari, Sina .

LANCET INFECTIOUS DISEASES, 2020, 21 (06) :746-748

[42] An mRNA Vaccine against SARS-CoV-2-Preliminary Report [J].

Jackson, L. A. ;

Anderson, E. J. ;

Rouphael, N. G. ;

Roberts, P. C. ;

Makhene, M. ;

Coler, R. N. ;

McCullough, M. P. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. ;

Flach, B. ;

Doria-Rose, N. A. ;

Corbett, K. S. ;

Morabito, K. M. ;

O'Dell, S. ;

Schmidt, S. D. ;

Swanson, P. A. ;

Padilla, M. ;

Mascola, J. R. ;

Neuzil, K. M. ;

Bennett, H. ;

Sun, W. ;

Peters, E. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Buchanan, W. ;

Pikaart-Tautges, R. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (20) :1920-1931

[43] Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine [J].

Jimenez-Guardeno, Jose M. ;

Regla-Nava, Jose A. ;

Nieto-Torres, Jose L. ;

DeDiego, Marta L. ;

Castano-Rodriguez, Carlos ;

Fernandez-Delgado, Raul ;

Perlman, Stanley ;

Enjuanes, Luis .

PLOS PATHOGENS, 2015, 11 (10)

[44] Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure [J].

Johnston, Sara C. ;

Ricks, Keersten M. ;

Jay, Alexandra ;

Raymond, Jo Lynne ;

Rossi, Franco ;

Zeng, Xiankun ;

Scruggs, Jennifer ;

Dyer, David ;

Frick, Ondraya ;

Koehler, Jeffrey W. ;

Kuehnert, Paul A. ;

Clements, Tamara L. ;

Shoemaker, Charles J. ;

Coyne, Susan R. ;

Delp, Korey L. ;

Moore, Joshua ;

Berrier, Kerry ;

Esham, Heather ;

Shamblin, Joshua ;

Sifford, Willie ;

Fiallos, Jimmy ;

Klosterman, Leslie ;

Stevens, Stephen ;

White, Lauren ;

Bowling, Philip ;

Garcia, Terrence ;

Jensen, Christopher ;

Ghering, Jeanean ;

Nyakiti, David ;

Bellanca, Stephanie ;

Kearney, Brian ;

Giles, Wendy ;

Alli, Nazira ;

Paz, Fabian ;

Akers, Kristen ;

Danner, Denise ;

Barth, James ;

Johnson, Joshua A. ;

Durant, Matthew ;

Kim, Ruth ;

Hooper, Jay W. ;

Smith, Jeffrey M. ;

Kugelman, Jeffrey R. ;

Beitzel, Brett F. ;

Gibson, Kathleen M. ;

Pitt, Margaret L. M. ;

Minogue, Timothy D. ;

Nalca, Aysegul .

PLOS ONE, 2021, 16 (02)

[45] RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE [J].

KIM, HW ;

CANCHOLA, JG ;

BRANDT, CD ;

PYLES, G ;

CHANOCK, RM ;

JENSEN, K ;

PARROTT, RH .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) :422-+

[46] Deaths From COVID-19 [J].

Koh, Howard K. ;

Geller, Alan C. ;

VanderWeele, Tyler J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (02) :133-134

[47] Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment [J].

Koyama, Takahiko ;

Weeraratne, Dilhan ;

Snowdon, Jane L. ;

Parida, Laxmi .

PATHOGENS, 2020, 9 (05)

[48] Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus [J].

Kuhn, JH ;

Li, W ;

Choe, H ;

Farzan, M .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (21) :2738-2743

[49] Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor [J].

Lan, Jun ;

Ge, Jiwan ;

Yu, Jinfang ;

Shan, Sisi ;

Zhou, Huan ;

Fan, Shilong ;

Zhang, Qi ;

Shi, Xuanling ;

Wang, Qisheng ;

Zhang, Linqi ;

Wang, Xinquan .

NATURE, 2020, 581 (7807) :215-+

[50] Rationalizing the development of live attenuated virus vaccines [J].

Lauring, Adam S. ;

Jones, Jeremy O. ;

Andino, Raul .

NATURE BIOTECHNOLOGY, 2010, 28 (06) :573-579

← 1 2 3 4 5 6 7 8 9 10 →